You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
|
|---|---|
| Published in |
BMC Urology, October 2013
|
| DOI | 10.1186/1471-2490-13-51 |
| Pubmed ID | |
| Authors |
Antoni Sicras-Mainar, Javier Rejas, Ruth Navarro-Artieda, Alba Aguado-Jodar, Amador Ruiz-Torrejón, Jordi Ibáñez-Nolla, Marion Kvasz |
| Abstract |
Overactive bladder (OAB) is associated with high healthcare costs, which may be partially driven by drug treatment. There is little comparative data on antimuscarinic drugs with respect to resource use and costs. This study was conducted to address this gap and the growing need for naturalistic studies comparing health economics outcomes in adult patients with OAB syndrome initiating treatment with different antimuscarinic drugs in a primary care setting in Spain. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 17% |
| Other | 5 | 14% |
| Student > Master | 4 | 11% |
| Student > Doctoral Student | 3 | 8% |
| Student > Bachelor | 2 | 6% |
| Other | 6 | 17% |
| Unknown | 10 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Social Sciences | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Other | 3 | 8% |
| Unknown | 11 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2013.
All research outputs
#15,238,214
of 22,736,112 outputs
Outputs from BMC Urology
#395
of 747 outputs
Outputs of similar age
#129,803
of 211,653 outputs
Outputs of similar age from BMC Urology
#7
of 11 outputs
Altmetric has tracked 22,736,112 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 747 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,653 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.